3 Horrendous Health-Care
Stocks This Week
Has the so-called biotech
bubble burst? Two of this
week’s most horrendous
health-care stocks bolster
the theory, while th...
The biotech’s shares plunged more than 46% for the week.
Exelixis (Nasdaq: EXEL)
Source: Yahoo! Finance
• It announced on Tuesday the
completion of an interim analysis of
Cometriq and that the phase 3
prostate cancer trial wou...
Shares of the cloud-based health-care technology company
dropped 27% this week.
Castlight Health (NYSE: CSLT)
Source: Yaho...
• Castlight’s IPO was last week, with
the stock vaulting nearly 150% on its
first day of trading.
• With only $13 million ...
The stock of the biopharmaceutical company fell 24% this week.
Galena Biopharma (Nasdaq: GALE)
Source: Yahoo! Finance
• This week’s decline appears to be a
continuation from last week’s
announcement of an SEC investigation.
• The investigat...
• While Castlight’s business model is
compelling, the stock really is
overpriced right now.
• Galena could certainly come ...
Find out which stock The Motley Fool’s chief
investment officer selected as the top pick for
2014 in our free report!
Upcoming SlideShare
Loading in …5
×

3 Horrendous Healthcare Stocks This Week 3-28-14

12,469 views

Published on

This week's most horrendous healthcare stocks.

Published in: Healthcare, Health & Medicine
0 Comments
5 Likes
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
12,469
On SlideShare
0
From Embeds
0
Number of Embeds
8,663
Actions
Shares
0
Downloads
17
Comments
0
Likes
5
Embeds 0
No embeds

No notes for slide
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-affymetrix-inc-shares-dropped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • http://www.fool.com/investing/general/2014/02/06/why-medidata-solutions-inc-shares-dipped.aspx
  • 3 Horrendous Healthcare Stocks This Week 3-28-14

    1. 3 Horrendous Health-Care Stocks This Week
    2. Has the so-called biotech bubble burst? Two of this week’s most horrendous health-care stocks bolster the theory, while the third stock could simply be experiencing the effects of market gravity. Source: Wikimedia Commons
    3. The biotech’s shares plunged more than 46% for the week. Exelixis (Nasdaq: EXEL) Source: Yahoo! Finance
    4. • It announced on Tuesday the completion of an interim analysis of Cometriq and that the phase 3 prostate cancer trial would continue to final analysis. • Many observers expected the study would be stopped early, as Johnson & Johnson’s Zytiga and Medivation’s Xtandi were. • Exelexis expects top-line data from the phase 3 study later this year. Why Exelixis got clobbered
    5. Shares of the cloud-based health-care technology company dropped 27% this week. Castlight Health (NYSE: CSLT) Source: Yahoo! Finance
    6. • Castlight’s IPO was last week, with the stock vaulting nearly 150% on its first day of trading. • With only $13 million in revenue, Castlight’s market cap hit $3 billion. • The backlash is apparently now under way, with plenty of critics. • Yahoo! Finance called Castlight the “most overpriced IPO of the century.” Why Castlight’s stock careened
    7. The stock of the biopharmaceutical company fell 24% this week. Galena Biopharma (Nasdaq: GALE) Source: Yahoo! Finance
    8. • This week’s decline appears to be a continuation from last week’s announcement of an SEC investigation. • The investigation stems from alleged questionable stock-promotions efforts by The DreamTeam Group, particularly involving the posting of positive articles about Galena. • Several online financial sites, including The Motley Fool, pulled articles related to the controversy over the past few months. Why Galena shares dropped
    9. • While Castlight’s business model is compelling, the stock really is overpriced right now. • Galena could certainly come back with good news from cancer immunotherapy Neuvax. • Exelixis gets the nod as the most likely to rebound. • Continuation of the Cometriq study was disappointing, but the market overreacted, in my view. Best shot at bouncing back?
    10. Find out which stock The Motley Fool’s chief investment officer selected as the top pick for 2014 in our free report!

    ×